Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Agmatine, a naturally occurring derivative of the amino acid arginine, has been investigated for its potential role in supporting or treating peripheral neuropathy. The scientific evidence for agmatine’s efficacy in this context is limited but promising, primarily coming from preclinical studies and a small number of clinical trials. Animal models of neuropathic pain have consistently shown that agmatine administration can reduce pain behaviors, likely due to its modulation of multiple molecular targets, including inhibition of NMDA receptors, stimulation of imidazoline receptors, and modulation of nitric oxide synthesis. These actions may help counteract mechanisms associated with nerve damage and pain. A small randomized, double-blind, placebo-controlled clinical trial (Keynan et al., 2010, Pain Medicine) involving patients with painful diabetic neuropathy showed that agmatine sulfate supplementation led to a statistically significant reduction in pain compared to placebo over a 2-month period. However, the sample size was relatively small (n=24), and replication in larger, more robust trials is needed to confirm efficacy and safety. Currently, agmatine is not a standard therapy for peripheral neuropathy, but early results suggest it may provide benefit, especially for neuropathic pain. Its use is supported by mechanistic plausibility and limited human evidence, thus meriting a moderate but not high evidence rating.

More about Agmatine
More about Peripheral Neuropathy

Other ingredients used for Peripheral Neuropathy

Other health conditions supported by Agmatine

Products containing Agmatine